Tallin capital city of Estonia

Riga, capital city of Latvia

Vilnius capital city of Lithuania

 

 

 

 

 

Pharmaceuticals And Healthcare Industry Analysis

Strengths

– Estonia invested in e-health and internationally recognised for its innovations.Most health care providers keep an electronic health record for patients and all health care providers are responsible for sending patient patient health care service provision information to the central health information system. The system allows e-consultations, digital referrals and e-prescriptions.

– Estonia, Latvia and Lithuania joined the EU in 2004 leading to the alignment of the baltic countries primary pharmaceuticals legislation with EU standards.

– Total health spending ultimately accounted for 6,7 % of GDP in Estonia and Lithuania in 2015, with per capita spending reaching EUR 1410 compared to the average of 9.9 % (EUR 2797) in the EU countries. However the share of public spending 76% is relatively high compared to neighbouring countries. In Latvia this figure is lower, 705 EUR per capita.

– In Latvia and Lithuania, medicines and other medical goods have bigger share in health expenditure than in Estonia – about 30% compared to 22% in Estonia. Lithuania invests more than others to long-term health care (8%).

Weaknesses

-The long-term financing adequacy of the Estonian health-care system has been a longstanding concern and well-documented challenge.  The current system, which is already one of the lowest spenders in Europe, is vulnerable to economic shocks and population ageing.

– The ageing workforce, emigration, and the health sectors’ ability to train more people sets limits to the number of professionals in the health workforce.

– There is a need to enhance provider activity evaluation and monitoring tools across the health system to improve quality and health outcomes.

 

 

default
hu_HU
en_US